Frances H. Arnold - 01 Sep 2026 Form 4 Insider Report for Generate Biomedicines, Inc. (GENB)

Reporting relationship: Director
Issuer ticker: GENB
Reported as of: 01 Sep 2026
Net transaction value: -$16,002
SEC form: 4
Accepted by SEC: 03 Sep 2026, 16:05:08 UTC
Prior SEC filing: 31 Aug 2026
Next SEC filing: 16 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Wolf, Attorney-in-Fact

Key filing fact

Frances H. Arnold filed Form 4 for Generate Biomedicines, Inc. (GENB) on 03 Sep 2026.

Key facts

This page summarizes Frances H. Arnold's Form 4 filing for Generate Biomedicines, Inc. (GENB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 16:05.

Change

Previous filing in this sequence was filed on 31 Aug 2026.
Current net transaction value: -$16,002.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001665419 Primary reporting owner

ARNOLD FRANCES

Relationship: Director
Address: GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE
Signature: /s/ Michael Wolf, Attorney-in-Fact
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GENB transaction

Common Stock

Sale

Transaction value: $16,002
Shares: -1,000
Change %: -0.43%
Price: $16.00
Shares after: 231,472
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2

GENB holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 232,472
Date: 01 Sep 2026
Ownership: By The Frances Arnold 2010 Irrevocable Trust
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.